Novocure Ltd (NVCR) Stock Price & Analysis
Novocure Ltd (NVCR) rose 2.31% to USD 17.24 as of June 10, 2026 at 01:58 UTC, according to Nexqual real-time market data.
NVCR last closed at USD 16.85; the session ranged USD 16.98–17.66 on volume of 1,380,122 shares. Market capitalization is $2.00B, with a 52-week range of USD 9.82–18.92 (NMS). Source: Nexqual, June 10, 2026 at 01:58 UTC.
Key Statistics (as of June 10, 2026 at 01:58 UTC)
| Price | USD 17.24 |
|---|---|
| Change | ▲ 2.31% (up) |
| Previous Close | USD 16.85 |
| Open | USD 17.07 |
| Day Range | USD 16.98 – 17.66 |
| 52-Week Range | USD 9.82 – 18.92 |
| Volume | 1,380,122 shares |
| Market Cap | $2.00B |
| Exchange | NMS |
Technical Analysis (NVCR)
Nexqual's technical model rates NVCR "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 01:58 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.46 (neutral) |
| vs SMA50 | Above (USD 14.73) |
| MACD | 0.48 (positive) |
Analyst Ratings (NVCR)
Wall Street analysts rate NVCR "None" based on 7 analysts, with a mean price target of USD 26.29 (range USD 17–48), per Nexqual as of June 10, 2026 at 01:58 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 26.29 |
| High Target | USD 48 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 5 / 2 / 0 |
Earnings (NVCR)
| Next Earnings Date | 2026-07-23 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $172.72M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.62 vs est -0.51 ▼ miss |
| 2025-12-31 | USD -0.22 vs est -0.41 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.42 ▲ beat |
| 2025-06-30 | USD -0.36 vs est -0.39 ▲ beat |
Source: Nexqual, June 10, 2026 at 01:58 UTC.
Financials & Fundamentals (NVCR)
| Total Revenue | $674.41M |
|---|---|
| Revenue Growth (YoY) | +12.30% |
| Gross Margin | +75.45% |
| Operating Margin | -38.73% |
| Profit Margin | -25.66% |
| ROE | -49.96% |
| Debt / Equity | 71.04 |
| Current Ratio | 2.9 |
| Total Cash | $432.00M |
| Total Debt | $234.94M |
| Free Cash Flow | $5.08M |
Source: Nexqual, June 10, 2026 at 01:58 UTC.
Financial Health Score (NVCR)
Nexqual rates Novocure Ltd's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:58 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 75%, operating -39% |
| Balance Sheet | Strong — $432M cash vs $235M debt, net cash position |
| Cash Flow | Mixed — FCF $5M, slim 0.8% margin |
| Efficiency | Critical — ROE -50%, ROA -11.1% |
Ownership (NVCR)
| Insider Ownership | +9.96% |
|---|---|
| Institutional Ownership | +87.62% |
| Shares Outstanding | 115.82M |
| Float | 95.25M |
| Short % of Float | +10.70% |
Source: Nexqual, June 10, 2026 at 01:58 UTC.
Leadership (NVCR)
Novocure Ltd is led by Frank Leonard, CEO & Director, per Nexqual as of June 10, 2026 at 01:58 UTC.
| CEO & Director | Frank Leonard |
|---|---|
| Executive Chairman | William F. Doyle (age 63) |
| Chief Financial Officer | Christoph Brackmann (age 51) |
| Chief Operating Officer | Mukund Paravasthu (age 55) |
Major Backers & Investors (NVCR)
Notable institutional backers of Novocure Ltd include FMR, LLC, Soleus Capital Management, L.P., Fidelity, according to Nexqual as of June 10, 2026 at 01:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.74% |
| Soleus Capital Management, L.P. | 9.06% |
| Fidelity | 8.74% |
| Morgan Stanley | 3.92% |
| Wells Fargo & Company | 2.55% |
| Quantinno Capital Management, LP | 2.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.67% |
| BlackRock | 14.17% |
| State Street | 2.21% |
| Geode Capital | 2.17% |
Source: Nexqual, June 10, 2026 at 01:58 UTC.
From Novocure Ltd's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
- Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
- The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GH | Guardant Health, Inc. | USD 130.12 | ▲ 3.59% |
| RGEN | Repligen Corporation | USD 130.13 | ▲ 6.39% |
| QDEL | QuidelOrtho Corporation | USD 13.94 | ▼ 2.72% |
| MASI | Masimo Corporation | USD 179.95 | ▲ 0.63% |
| DXCM | DexCom, Inc. | USD 78.19 | ▲ 7.32% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:58 UTC. This page is informational and not investment advice.